- Home
- Analyses d’applications gratuites
- MAQI2 Anticoagulation Toolkit
- MAQI2 Anticoagulation Toolkit Vs. AnticoagEvaluator
MAQI2 Anticoagulation Toolkit vs AnticoagEvaluator Utilisation & Stats
This mobile app provides healthcare practitioners with an up-to-date, easy-to-use resource for managing anticoagulation patients more safely and effectively. The content was developed by the Michigan Anticoagulation Quality Improvement Initiative (MAQI2), a Blue Cross Blue Shield/Blue Care Network of Michigan sponsored consortium of anticoagulation clinics and experts from across the state of Michigan, and is based on the latest guidelines and research.
- Apple App Store
- Gratuit
- Médical
Classement dans le store
- -
Make well-informed decisions on antithrombotic therapy for your non-valvular AF patients with the updated AnticoagEvaluator.
Use the app to:
• Calculate a patient's renal function and risk of ischemic stroke, thromboembolism, and bleed
• Review ACC/AHA/HRS Guideline-driven therapy guidance for stroke prevention
• Generate individualized risk for antithrombotic therapy options based on individual clinical trials.
• Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics.
This app is based on SPARC Tool, developed by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at www.sparctool.com
- Apple App Store
- Gratuit
- Médical
Classement dans le store
- -
Comparaison des classements MAQI2 Anticoagulation Toolkit vs. AnticoagEvaluator
Comparez l'évolution du classement de MAQI2 Anticoagulation Toolkit au cours des 28 derniers jours à celle de AnticoagEvaluator.
Rank
Aucune donnée disponible
Comparaison des classements MAQI2 Anticoagulation Toolkit et AnticoagEvaluator par pays
Comparez l'évolution du classement de MAQI2 Anticoagulation Toolkit au cours des 28 derniers jours à celle de AnticoagEvaluator.
Aucune donnée à afficher
Comparez avec n'importe quel site grâce à notre essai gratuit
MAQI2 Anticoagulation Toolkit VS.
AnticoagEvaluator
janvier 8, 2025